Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study

American Journal of Nephrology

Volumn 42, Issue 5, 2015, Pages 351-360

  Loutradis, Charalampos ^a   Tolika, Panagiota ^b   Skodra, Alexandra ^b   Avdelidou, Afroditi ^b   Sarafidis, Pantelis A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b General Hospital of Grevena   (Greece)

Author keywords

Angiotensin converting enzyme inhibitors; Chronic kidney disease; Diabetes; Hyperkalemia

Indexed keywords

ALISKIREN; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; POLYSTYRENESULFONATE SODIUM; POTASSIUM; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGE; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC PATIENT; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON DIABETIC PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; POTASSIUM BLOOD LEVEL; POTASSIUM HOMEOSTASIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC COMPLICATION;

AGED; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERKALEMIA; MALE; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84948651341     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000442393     Document Type: Article

References (28)

1. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156-1162.
2. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S: Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012;109:1510-1513.
3. Palmer BF: A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 2010;56:387-393.
4. Winkelmayer WC: Treatment of hyperkalemia: from 'hyper K+' strikeout to home run? JAMA 2015;314:129-130.
5. Takaichi K, Takemoto F, Ubara Y, Mori Y: The clinically significant estimated glomerular filtration rate for hyperkalemia. Intern Med 2008;47:1315-1323.
6. Lazich I, Bakris GL: Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014;34:333-339.
7. Sarafidis PA, Bakris GL: Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-1757.
8. Weir MR, Rolfe M: Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010;5:531-548.
9. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K: Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012;7:1234-1241.
10. Pappoe LS, Winkelmayer WC: ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging 2010;27:87-94.
11. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC: Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-1665.
12. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M'rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009;20:164-171.
13. Drawz PE, Babineau DC, Rahman M: Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012;60:310-315.
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(suppl 1):S62-S69.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
16. Summary of recommendation statements. Kidney Int Suppl (2011) 2013;3:5-14.
17. Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJ: eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009;20:722-727.
18. Liamis G, Liberopoulos E, Barkas F, Elisaf M: Diabetes mellitus and electrolyte disorders. World J Clin Cases 2014;2:488-496.
19. Khosla N, Kalaitzidis R, Bakris GL: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009;30:418-424.
20. Sarafidis PA, Ruilope LM: Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 2014;85:536-546.
21. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-2092.
22. Grassi G, Seravalle G, Calhoun DA, Bolla G, Mancia G: Cigarette smoking and the adrenergic nervous system. Clin Exp Hypertens A 1992;14:251-260.
23. Moratinos J, Reverte M: Effects of catecholamines on plasma potassium: the role of alpha-and beta-adrenoceptors. Fundam Clin Pharmacol 1993;7:143-153.
24. Amir O, Hassan Y, Sarriff A, Awaisu A, Abd Aziz N, Ismail O: Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases. Pharm World Sci 2009;31:387-393.
25. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP: Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 2012;120:c8-c16.
26. Sarafidis PA, Georgianos PI, Bakris GL: Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother 2015;16:2205-2215.
27. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators: Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-161.
28. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B: Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372:222-231.